Advancing Immune-Based Therapies for Precision Medicine and Disease Modulation

At the LORD Lab, we are advancing our understanding of immune-based therapies to tackle chronic inflammation, autoimmune diseases, type 2 diabetes, and kidney transplant rejection. Our research focuses on immune tolerance, biomarker discovery, and precision medicine, using cutting-edge technologies such as CRISPR gene editing, single-cell RNA sequencing (scRNA-seq), and spatial omics to uncover molecular mechanisms and develop targeted, long-lasting treatments.

A key focus of our work is investigating regulatory T cells (Tregs) and microRNA-142, both essential for immune balance. Tregs suppress inflammation, while microRNA-142 regulates immune responses at the molecular level. Disruptions in either contribute to disease, making them promising therapeutic targets.

Our translational approach bridges fundamental immunology and clinical application, with an emphasis on personalised medicine and cell-based therapies. Through collaborative research and advanced technologies, we aim to shape the future of immune-based treatments.